Yumanity Therapeutics, Inc. (YMTX) Balance Sheet Annual - Discounting Cash Flows
YMTX
Yumanity Therapeutics, Inc.
YMTX (NASDAQ)
Period Ending: 2024
12-31
Report Filing: 2025-03-06
Total Current Assets 1.02
Cash and Short Term Investments 0.634
Cash & Equivalents 0.634
Short Term Investments 0
Receivables 0
Inventory 0
Other Current Assets 0.385
Total Assets 1.02
Total Non-Current Assets 0
Property, Plant and Equipment 0
Goodwill and Intangible Assets 0
Goodwill 0
Intangible Assets 0
Long Term Investments 0
Deferred Tax Assets 0
Other Long Term Assets 0
Total Current Liabilities 12.89
Accounts Payable 3.9
Notes Payable/Short Term Debt 0.629
Tax Payables 0
Deferred Revenue 0
Other Current Liabilities 8.36
Total Liabilities 12.89
Total Non-Current Liabilities 0
Total Long Term Debt 0
Deferred Tax Liabilities Non-Current 0
Deferred Revenue Non-Current 0
Capital Lease Obligations 0
Other Long Term Liabilities 0
Total Equity 0
Non-Controlling Interest 0.164
Total Stockholders' Equity -12.03
Retained Earnings -182.9
Accumulated Other Earnings 0
Common Stock 0.012
Preferred Stock 0
Additional Paid in Capital 170.9
Total Liabilities & Total Equity 1.02
Total Liabilities & Shareholders' Equity 1.02
Total Investments 0
Total Debt 0.629
Net Debt -0.005
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program